In the last few years there has been significant improvement in the imaging of prostate cancer using Prostate Specific Membrane Antigen (PSMA) PET. We were the first institution in the United States to imaging patients using 68Ga-PSMA-11, otherwise known as the Heidelberg compound of HBED-CC PSMA. We are involved in a multicenter trial to obtain data that will eventually lead to the FDA approval of the compound. We are also progressing towards creating a trial using PSMA-617 as a targeted therapy treatment.
PSMA PET/MRI demonstrating uptake in a high grade primary tumor. Diffusion weighted imaging (top right) and the associated ADC map (bottom right) demonstrated restricted diffusion, which correlates with the tumor seen on PSMA PET (bottom left). Fused T2 weighted images (top right) demonstrates extracapsular extension.
Clinical Trials
- Initial evaluation of PSMA PET in prostate cancer patients (NCT02611882)
- Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients (NCT0291911)
- Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence (NCT02918357)
Publications
- Hope TA, Truillet CC, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience. J Nucl Med. 2016 Sep 22.
- Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, Eder M, Eisenhut M, Kopka K, Haberkorn U. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1611-20.